## SCIENCEDOMAIN international

www.sciencedomain.org



## **SDI FINAL EVALUATION FORM 1.1**

## PART 1:

Journal Name:	British Journal of Pharmaceutical Research
Manuscript Number:	2013_BJPR_8495
Title of the Manuscript:	FORMULATION and EVALUATION of OPTIMIZED CLOTRIMAZOLE EMULGEL FORMULATIONS

## PART 2:

PART 2:	
FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
1. In drug content determination (2.2.3.2), the methodology needs to be better explained in the paper.	-Done line:108-112
2. In 2.2.3.4, considering that "in vitro" release studies used the "sink conditions", please, inform it in the manuscript;	-Done line:127
3. The methodology used in 2.2.3.6. needs to be better explained;	-Done line 137-139
4. To conclude the magnitude of pseudoplastic behavior, the authors needs to apply Oswald-de-Waele equation, since it is possible with the data obtained.	-The equation has been added ,line: 117 -121 And 180-182
5. The description of the Canesten cream composition, is possible, since all package possess qualitative information about composition;	-On the package the only data present that: the tube 20 gms contain 0.2gm Clotrimazole i.e. 1% mentioned at line 54
6. To do a conclusion, the authors needs to present an statistical analysis of the data, then, I strongly suggest that "in vitro drug release" present the results revised after the statistical test. Statistical analysis is the basis of scientific conclusions, then, this is essential to publish the results obtained.	-ANOVA study has been done and mentioned at line 288-292

Created by: EA Checked by: ME Approved by: CEO Version: 1.5 (4<sup>th</sup> August, 2012)